BriaCell Therapeutics Corp. (BCTXZ)
NCM
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Quarterly Financials
| Metric | 2025-04-30 | 2025-10-31 | 2026-01-31 | 2026-04-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.3M | -8.3M | -7.5M | -7.6M |
| Net Income | -6.1M | -8.2M | -7.2M | -7.2M |
Annual Financials
| Metric | 2021-07-31 | 2022-07-31 | 2023-07-31 | 2024-07-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.0M | -15.3M | -23.3M | -33.3M |
| Net Income | -13.8M | -26.8M | -20.3M | -4.8M |